|
NEWS CENTER
DOR
BioPharma 2006 News Archive.
Dec
7, 2006
DOR
BioPharma Announces Notice of Allowance for Key
Ricin Toxin Vaccine Patent
Nov
28, 2006
European
Medicines Agency Accepts DOR BioPharma’s MAA
Filing for orBec®
Nov
21, 2006
FDA
Accepts DOR BioPharma’s NDA Filing for orBec®
Nov
15, 2006
DOR
BioPharma Reports Advances in Stabilization and
Optimization of RiVaxTM Vaccine Formulation.
Nov
14, 2006
DOR
BioPharma Reports Third Quarter Financial Results,
Reviews Recent Achievements.
Nov
7, 2006
DOR
BioPharma Submits European Marketing Application
for orBec® to Treat GI Graft-versus-Host Disease.
orBec® is First Directed Therapy for GI GVHD.
Nov
3 , 2006
DOR
BioPharma to Present at the Rodman & Renshaw
8th Annual Healthcare Conference.
Webcast
Link on DOR’s Redesigned Website.
Oct
31 , 2006
DOR
BioPharma Announces New Collaborations for Ricin
Vaccine Development. Company accelerates RiVaxTM
development through NIH cooperative consortium.
Sep
29 , 2006
DOR
BioPharma Awarded Two Grants Totaling $5.3 Million
to Advance Ricin Toxin and Botulinum Toxin Vaccine
Programs
Sep
22 , 2006
DOR
BioPharma Files New Drug Application with FDA to Market
orBec® for GI GVHD.
First GI-Directed Therapy to Treat the Most Common Life
Threatening Complication of Hematopoietic Stem Cell
Transplantation.
Aug
30 , 2006
DOR BioPharma
Announces the Appointment of Christopher J. Schaber,
Ph.D. as its new President and Chief Executive Officer
and Changes in its Board of Directors .
Aug
14, 2006
DOR BioPharma,
Inc. Reports Second Quarter 2006 Financial Results and
Reviews Achievements
Jul
6 , 2006
DOR BioPharma
Announces Successful Completion of cGMP Production Milestone
for RiVax™.
June
30, 2006
DOR
BioPharma Provides Regulatory Update on orBec®
May
15, 2006
DOR
BioPharma to Present at the Rodman & Renshaw 3rd Annual
Global Healthcare Conference.
May
15 2006
DOR BioPharma,
Inc. Reports First Quarter 2006 Financial Results and
Reviews Achievements..
Apr
24, 2006
DOR
BioPharma Granted SME Status by the European Commission
and the EMEA.
Apr
18, 2006
DOR
BioPharma Announces New Stock Symbol DORB.
Apr
7 , 2006
DOR BioPharma
Announces Advances in Mucosal Vaccines for Botulinum
Toxin. Antigens are made using Dowpharma's Pf nex Expression
Technology.
Apr
6, 2006
DOR
BioPharma Announces Private Equity Financing of $3.65
Million With Institutional Investors.
Mar
30, 2006
DOR
BioPharma Reports Year End 2005 Financial Results and
Accomplishments. DOR Provides Guidance on Regulatory
Filings on orBec®.
Feb
21, 2006
DOR BioPharma
Presents Positive New Survival Findings from Phase II
and III Clinical Trials of orBec® at Annual Bone Marrow
Transplant Conference. Abstract Selected for Best Abstracts
Award.
Feb
8, 2006
DOR
BioPharma Provides Financial Guidance and Update on
European Regulatory Plans for orBec® .
Jan
30, 2006
DOR
BioPharma Announces Positive Phase I Results of RiVax™,
its Vaccine Against Ricin Toxin Vaccine is immunogenic
and well tolerated.
Jan
26, 2006
DOR BIOPHARMA
INC Files SEC form 8-K, Other Events.
Jan
25 , 2006
DOR
BioPharma Achieves Manufacturing Milestone in Development
of RiVax™ DOR and its collaborators achieve 2nd milestone
ahead of schedule.
Jan
21, 2006
DOR
BioPharma Reports Positive New Survival Findings
from Previously Completed Phase II and III Clinical
Trials of orBec®.
|
